These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 35822340)

  • 1. Comparing the activity of novel antibiotic agents against carbapenem-resistant Enterobacterales clinical isolates.
    Tamma PD; Bergman Y; Jacobs EB; Lee JH; Lewis S; Cosgrove SE; Simner PJ;
    Infect Control Hosp Epidemiol; 2023 May; 44(5):762-767. PubMed ID: 35822340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Activities of Novel Therapeutic Agents against Molecularly Characterized Clinical Carbapenem-Resistant
    Teo JQ; Chang HY; Tan SH; Tang CY; Ong RT; Ko KKK; Chung SJ; Tan TT; Kwa AL
    Microbiol Spectr; 2023 Jun; 11(3):e0100223. PubMed ID: 37184408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates.
    Maraki S; Mavromanolaki VE; Magkafouraki E; Moraitis P; Stafylaki D; Kasimati A; Scoulica E
    Infection; 2022 Apr; 50(2):467-474. PubMed ID: 34854060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
    Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
    Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam.
    Kang MS; Baek JY; Ko J-H; Cho SY; Lee KY; Lee YH; Yang J; Kim TY; Huh HJ; Lee NY; Huh K; Kang C-I; Chung DR; Peck KR
    Microbiol Spectr; 2024 Jun; 12(6):e0034424. PubMed ID: 38687076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of ceftazidime/avibactam and plazomicin on carbapenem-resistant Klebsiella pneumoniae and Escherichia coli.
    Öztaş S; Er DK; Dündar D; Keçeli SA
    Acta Microbiol Immunol Hung; 2024 Jul; 71(2):110-120. PubMed ID: 38837219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020-2022).
    Sader HS; Carvalhaes CG; Kimbrough JH; Mendes RE; Castanheira M
    Int J Antimicrob Agents; 2024 Apr; 63(4):107113. PubMed ID: 38354826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant
    Shortridge D; Kantro V; Castanheira M
    Microbiol Spectr; 2023 Feb; 11(1):e0450722. PubMed ID: 36622238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imipenem-Relebactam Susceptibility in
    Hernández-García M; García-Castillo M; Bou G; Cercenado E; Delgado-Valverde M; Oliver A; Pitart C; Rodríguez-Lozano J; Tormo N; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Cruz H; Chaves C; Duarte J; Pássaro L; Díaz-Regañón J; Cantón R
    Microbiol Spectr; 2022 Oct; 10(5):e0292722. PubMed ID: 36043877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018-2022).
    Sader HS; Mendes RE; Duncan L; Kimbrough JH; Carvalhaes CG; Castanheira M
    Diagn Microbiol Infect Dis; 2023 Jun; 106(2):115945. PubMed ID: 37060707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam.
    Di Pilato V; Principe L; Andriani L; Aiezza N; Coppi M; Ricci S; Giani T; Luzzaro F; Rossolini GM
    Clin Microbiol Infect; 2023 Apr; 29(4):537.e1-537.e8. PubMed ID: 36414199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility of OXA-48-producing Enterobacterales to imipenem/relebactam, meropenem/vaborbactam and ceftazidime/avibactam.
    Bonnin RA; Bernabeu S; Emeraud C; Creton E; Vanparis O; Naas T; Jousset AB; Dortet L
    Int J Antimicrob Agents; 2022 Oct; 60(4):106660. PubMed ID: 35988666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of KPC Variant and Porin Genotype on the
    Wilson WR; Kline EG; Jones CE; Morder KT; Mettus RT; Doi Y; Nguyen MH; Clancy CJ; Shields RK
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland.
    Nordmann P; Bouvier M; Poirel L
    Eur J Clin Microbiol Infect Dis; 2023 Sep; 42(9):1145-1152. PubMed ID: 37566365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [In Vitro Activity of Ceftazidime-avibactam and Colistin Against Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates].
    Hoşbul T; Aydoğan CN; Kaya S; Bedir O; Gümral R; Albay A
    Mikrobiyol Bul; 2022 Apr; 56(2):218-229. PubMed ID: 35477226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales.
    Bonnin RA; Bernabeu S; Emeraud C; Naas T; Girlich D; Jousset AB; Dortet L
    Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671303
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Santerre Henriksen A; Arena F; Attwood M; Canton R; Gatermann S; Naas T; Morrissey I; Longshaw C;
    Microbiol Spectr; 2024 Jun; 12(8):e0418123. PubMed ID: 38904361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vitro Susceptibility to Ceftazidime-Avibactam and Comparator Antimicrobial Agents of Carbapenem-Resistant Enterobacterales Isolates.
    Lim TP; Ho JY; Teo JQ; Sim JH; Tan SH; Tan TT; Kwa AL
    Microorganisms; 2023 Aug; 11(9):. PubMed ID: 37764002
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Adams J; Santarossa M; Harrington A; Bauer M; Wozniak A; Labuszewski L; Albarillo FS
    Infect Dis (Lond); 2023 Apr; 55(4):282-291. PubMed ID: 36772806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
    Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
    Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.